Related Experiment Video

Updated: Aug 24, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer]

Hideto Kimata1, Osamu Teshigahara, Yukihiro Nishiyama

  • 1Department of Surgery II, Graduate School of Medicine, Nagoya University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 20, 2004
PubMed

Insights

Oncolytic herpes simplex virus type 1 mutant HF10 shows significant anti-tumor efficacy in mouse models. Surviving mice developed resistance, and clinical trials for metastatic breast cancer are showing promising early results.

Area of Science:

  • Virology
  • Immunology
  • Oncology

Context:

  • Oncolytic viruses represent a promising cancer therapy.
  • Herpes simplex virus type 1 (HSV-1) mutants are being explored for oncolytic potential.
  • HF10 is a specific HSV-1 mutant engineered for anti-tumor activity.

Purpose:

  • To evaluate the anti-tumor efficacy of the oncolytic herpes simplex virus type 1 mutant HF10.
  • To assess the development of tumor resistance in surviving subjects.
  • To investigate the safety and preliminary efficacy of HF10 in human clinical trials for metastatic breast cancer.

Summary:

  • The HF10 mutant demonstrated significant anti-tumor efficacy in syngeneic immuno-competent mouse models.
  • All surviving mice in the study acquired resistance to subsequent tumor cell rechallenge, indicating a potential immune-mediated effect.
  • Based on its efficacy and safety profile in preclinical models for various cancers, HF10 is now undergoing Phase I/II clinical trials for metastatic breast cancer patients.

Impact:

  • HF10 shows potential as an effective oncolytic virotherapy agent.
  • The development of acquired resistance suggests a role for the host immune system in HF10's anti-cancer effects.
  • Encouraging preliminary data from ongoing clinical trials suggest HF10 could offer a new therapeutic option for cancer patients, particularly those with metastatic breast cancer.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...